AxioMed, NanoFuse Biologics could sell in 3 to 5 years — 4 insights

KICVentures is seeking investors to ready AxioMed and NanoFuse Biologics for possible acquisition in the next three to five years.

Advertisement

What you should know:

1. KICVentures will be at the American Academy of Orthopedic Surgeons annual meeting in Las Vegas, March 12-16.

2. The investments will be used to prepare AxioMed and NanoFuse for a possible acquisition.

3. KICVentures is seeking a minimum investment of $25,000.

4. KICVentures Founder Kingsley R. Chin, MD, said, “Consolidation and market expansion will continue for the next five years as larger device players respond to growth pressures and to new innovations in the areas of motion preservation and biologics.”

More articles on devices:
21 spine devices receive FDA 510(k) clearance in January
Medtronic reports $7.5B in Q3 revenue & more: 12 device company notes
4 things to know about pedicle screw design

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.